Skip to main content
. 2021 Nov 24;12:752233. doi: 10.3389/fimmu.2021.752233

Table 2.

Multiple linear regression analyses showing average changes of SARS-CoV2 IgG and neutralizing antibodies.

Variable IgG (BAU/ml)* Neutralizing (%)*
Change 95% CI p-value Change 95% CI p-value
Diabetic vs. Non-Diabetic −13.86 [−27.08 to −0.64] 0.041 −4.42 [−8.53 to −0.32] 0.036
Hypertensive vs. Not Hypertensive 4.00 [−9.95 to 17.95] 0.575 0.75 [−3.59 to 5.1] 0.734
Age (per 1 year increase) −0.43 [−0.86 to 0] 0.049 −0.25 [−0.38 to -0.12] <0.001
Male vs. Female −3.52 [−15 to 7.96] 0.548 −0.31 [−3.87 to 3.26] 0.865
BMI between 25 and 30 vs. BMI < 25 −8.70 [−22.58 to 5.19] 0.221 −1.91 [−6.29 to 2.46] 0.392
BMI Greater than 30 vs. BMI < 25 −5.76 [−21.57 to 10.05] 0.476 −0.33 [−5.3 to 4.63] 0.895
Previous COVID-19 Infection vs. None 38.50 [23.05 to 53.96] <0.001 7.11 [2.31 to 11.91] 0.004
Comorbidity score (per 1 score increase) 4.99 [−3.12 to 13.1] 0.229 1.21 [−1.35 to 3.77] 0.354

*All models were adjusted for the variables mentioned in addition to duration since second dose of BNT162b2 (Pfizer–BioNTech) vaccine, which was modeled non-linearly with penalized splines in generalized additive models.